Explore 3 Stock Ideas & Industry Insights Download Free Report

News

PRF Technologies (Nasdaq: PRFX) Points GridFeed AI Platform at Hyperscale Data Centers

The move extends strategic momentum from a September 9, 2026 restructuring in which PRF Technologies (Nasdaq: PRFX) established GridFeed as a dedicated corporate unit focused on forming alliances with data center operators. The initiative seeks to give operators enhanced capacity management tools, reduced electricity …

Nitish Kishor | 17 September 2026

Regeneron (Nasdaq: REGN) Reports 90.5% Disease Control Rate for Ateganosine in Advanced NSCLC

The update follows earlier positive initial efficacy data from Part C of the Phase 2 expansion trial, which evaluated ateganosine followed by cemiplimab in third-line advanced NSCLC. That cohort showed an interim disease control rate of 90.5%, data that had been noted on July …

Nitish Kishor | 17 September 2026

Tiziana Life Sciences (Nasdaq: TLSA) Signs MOU to Expand Foralumab Testing in Non-Responding RRMS

The new collaboration sits alongside Tiziana Life Sciences' (Nasdaq: TLSA) ongoing, blinded Phase 2 trial in non-active secondary progressive multiple sclerosis, for which a data readout remains on track for October 2026. Together, the two programs broaden the company's multiple sclerosis pipeline across different …

Nitish Kishor | 17 September 2026

Tempest Therapeutics (Nasdaq: TPST) Expands CAR-T Reach With Senlang Licensing Deal

The option agreement is designed to complement Tempest Therapeutics' (Nasdaq: TPST) own CD7-targeted lipid nanoparticle in vivo CAR-T platform, which remains in earlier-stage development. By adding a lentiviral vector approach through Senlang, the company gains a second, potentially more durable route to generating CAR-T …

Nitish Kishor | 17 September 2026

Xenetic Biosciences (Nasdaq: XBIO) to Merge With Santersus AG, Form Santersus Bio

The combined company will be guided by Santersus Chief Executive Officer James Ladtkow and will carry forward a four-program clinical portfolio centered on neutrophil extracellular traps, or NETs. The pipeline is headlined by two candidates that hold FDA Breakthrough Device designation in pivotal-phase development …

Nitish Kishor | 17 September 2026

NanoViricides (NYSE: NNVC) to Begin Dosing Oral Ebola Candidate NV-387 in DRC Phase 2 Trial

The clinical program is structured in two stages. An initial single-arm Phase 2a cohort will assess safety, followed by a randomized Phase 2b stage evaluating therapeutic efficacy. If NV-387 advances through this pathway, NanoViricides (NYSE: NNVC) said it would represent the only oral therapeutic …

Nitish Kishor | 17 September 2026

Nuvation Bio (NYSE: NUVB) Wins FDA Approval to Update IBTROZI Label With 49.7-Month Duration of Response Data

Extended monitoring of the TRUST-I study population revealed no novel safety concerns and required no modifications to the existing safety labeling for IBTROZI, according to Nuvation Bio (NYSE: NUVB).

Nitish Kishor | 17 September 2026

Oragenics (NYSE American: OGEN) Activates Third Australian Site for ONP-002 Concussion Trial

The Australian program builds on earlier progress, including the enrollment of the trial's first patient and a Type B meeting request submitted to the FDA to advance the U.S. regulatory pathway for ONP-002. Oragenics (NYSE American: OGEN) has said it plans to submit an …

Nitish Kishor | 17 September 2026

OS Therapies (NYSE: OSTX) Aligns With European Regulators on Adaptive Phase 3 Design for OST-HER2

The company is targeting clinical trial startup in the fourth quarter of 2026, alongside a pre-BLA Type B discussion with the FDA scheduled for late 2026. OS Therapies (NYSE: OSTX) said the program is supported by leadership from the UK's MHRA within Project Orbis, …

Nitish Kishor | 17 September 2026

AbCellera Biologics (Nasdaq: ABCL) to Present Menopause Candidate Data at IMS World Congress

The upcoming presentation follows earlier Phase 1/2 topline results in which ABCL635 met its primary efficacy endpoints, achieving statistically significant reductions in both the frequency and severity of vasomotor symptoms at week four compared with placebo, after just a single dose. AbCellera Biologics (Nasdaq: …

Nitish Kishor | 17 September 2026
Support

Hi! How can we help you today?

Loading…